These findings supported the notion that BGB‐283 prevented MEKi‐induced MAPK feedback signaling through RAF dimer inhibition and improved the antitumor activity of MEKi in K‐RAS‐mutated cancers. The gene discussed is RAF1; the disease is cancer.